Meetings

ClinPGx 2024 Meeting Registration open
ClinPGx Logo

In collaboration with CPIC, PharmGKB, PharmCAT and PharmVar, the Penn Institute for Biomedical Informatics will be hosting the ClinPGx 2024: Knowledge, Implementation, Education meeting on June 20th and 21st, 2024 in Philadelphia, PA. This meeting will provide educational content to cover all aspects of PGx implementation.

Participants are invited to submit abstracts for the poster sessions. You must be registered for the meeting before your abstract will be accepted.

Please note breakfast & lunch will be provided all conference days.

ClinPGx 2024 Meeting Agenda

Registration

REMINDERS / DEADLINES:

March 22, 2024: Deadline for Abstract Submission. Abstract submission form link here.

April 30, 2024: Deadline for $350 Registration Fee (Starting May 1st, registration fee will be $450)

May 20, 2024: Deadline for Hotel Reservations. Click HERE for hotels offering special rates.

June 1, 2024: Deadline to register for the event.

2022 CPIC meeting

The 2022 CPIC-PGRN meeting: Diversifying PGx Science to Improve Implementation was held at the University of Colorado on May 10th, 11th, and 12th in Denver, CO.

2019 CPIC meeting

The CPIC Meeting was held in Memphis, TN at St. Jude Children’s Research Hospital on June 6th (full day) and June 7th (1/2 day).

2017 CPIC meeting 

The CPIC Meeting was held on March 15, 2017, in conjunction with the 2017 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) on March 15-18, 2017 (Washington, DC).

The one-day symposium was organized by the Clinical Pharmacogenetics Implementation Consortium (CPIC®) (www.cpicpgx.org) as part of the Pharmacogenomics Research Network (PGRN) (www.pgrn.org).   The CPIC-PGRN Meeting was open to all and featured presentations from a world-class group of speakers who described current examples of implementation of pharmacogenomics in the clinic. There was also panel discussions to summarize topics and encourage audience participation. Presentations included “best cases” as well as challenging cases for implementation, and included international perspectives on clinical use of pharmacogenomics.